Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kaitlyn K.H. Goey"'
Autor:
Kaitlyn K.H. Goey, Harpreet Wasan, Aimery de Gramont, Benoist Chibaudel, Tim Maughan, Axel Hinke, Roberto Labianca, Cornelis J A Punt, Kjell Magne Tveit, Susanna Hegewisch-Becker, Louise J. Brown, David E. Fisher, Richard Kaplan, Richard Adams, Eduardo Diaz Rubio, Dirk Arnold, Miriam Koopman
Publikováno v:
Cancer treatment reviews. 99
Background\ud Intermittent systemic anti-cancer therapy in patients with advanced colorectal cancer (aCRC) may improve quality of life without compromising overall survival (OS). We aimed to use individual patient data meta-analysis (IPDMA) from mult
Autor:
K. L. van Rooijen, Kaitlyn K.H. Goey, A. de Gramont, Eduardo Díaz-Rubio, Erin M. Green, C.J.A. Punt, Alfredo Falcone, Jeffrey P. Meyers, Q. Shi, Enrique Aranda, Miriam Koopman, Daniel J. Sargent, Volker Heinemann
Publikováno v:
European Journal of Cancer, 91, 99. Elsevier Limited
European journal of cancer (Oxford, England, 91, 99-106. Elsevier Limited
European journal of cancer (Oxford, England, 91, 99-106. Elsevier Limited
Indication for primary tumour resection (PTR) in asymptomatic metastatic colorectal cancer (mCRC) patients is unclear. Previous retrospective analyses suggest a survival benefit for patients who underwent PTR. The aim was to evaluate the prognostic v
Autor:
G.J.M. Creemers, Stefan M. Willems, Eric Strengman, A.M.T. van der Velden, A.J. ten Tije, W. W. J. de Leng, Frans L. G. Erdkamp, C.J.A. Punt, Miangela M. Lacle, B.C. Tanis, Kaitlyn K.H. Goey, F. de Jongh, Sjoerd G. Elias, Miriam Koopman, G J A Offerhaus, H. van Tinteren
Publikováno v:
Annals of Oncology, 28(9), 2128. Oxford University Press
Annals of oncology, 28(9), 2128-2134. Oxford University Press
Annals of oncology, 28(9), 2128-2134. Oxford University Press
Background The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without co
Autor:
Martijn G.H. van Oijen, Sjoerd G. Elias, Cornelis J. A. Punt, Kaitlyn K.H. Goey, Miriam Koopman, Susanna Hegewisch-Becker, Dirk Arnold, Axel Hinke
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
British Journal of Cancer
British journal of cancer, 117(12), 1768-1776. Nature Publishing Group
British Journal of Cancer, 117(12), 1768. Nature Publishing Group
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
British Journal of Cancer
British journal of cancer, 117(12), 1768-1776. Nature Publishing Group
British Journal of Cancer, 117(12), 1768. Nature Publishing Group
BACKGROUND: The CAIRO3 and AIO 0207 trials demonstrated the efficacy of fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment in metastatic colorectal cancer (mCRC) patients. In this individual patient data meta-analysis with updated follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c748f5c8768148ec04b924f0db51db8a
Autor:
S. Hegewisch Becker, M. G. H. van Oijen, M. Koopman, C.J.A. Punt, Kaitlyn K.H. Goey, Sjoerd G. Elias, Dirk Arnold, Axel Hinke
Publikováno v:
Annals of oncology, 27. Oxford University Press
Autor:
Johannes H. W. de Wilt, Martijn G.H. van Oijen, Jorine 't Lam-Boer, Miriam Koopman, Cornelis J. A. Punt, Kaitlyn K.H. Goey
Publikováno v:
European Journal of Cancer, 69, 166. Elsevier Limited
European Journal of Cancer, 69, 166-177
European Journal of Cancer, 69, pp. 166-177
European Journal of Cancer, 69, 166-177
European Journal of Cancer, 69, pp. 166-177
Item does not contain fulltext BACKGROUND: Although synchronous and metachronous metastases are considered as separate entities of metastatic colorectal cancer (mCRC) with different outcomes, its proportion is reported infrequently. We compared inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fae9728376ce3289344f1630f783858
https://doi.org/10.1016/j.ejca.2016.09.028
https://doi.org/10.1016/j.ejca.2016.09.028
Autor:
Remi Mahmoud, Cornelis J. A. Punt, Bengt Glimelius, Miriam Koopman, Claus Henning Köhne, Martijn G.H. van Oijen, Halfdan Sorbye, Kaitlyn K.H. Goey, Daniel J. Sargent
Publikováno v:
European Journal of Cancer, 96, 115. Elsevier Limited
Background Patient characteristics and stratification factors are important factors influencing trial outcomes. Uniform reporting on these parameters would facilitate cross-study comparisons and extrapolation of trial results to clinical practice. In
Autor:
A. de Gramont, Harpreet Wasan, Louise Brown, R. Labianca, Punt Cja., Susanna Hegewisch-Becker, Axel Hinke, Dirk Arnold, Richard Adams, David Fisher, Richard Kaplan, Miriam Koopman, Kjell Magne Tveit, Tim Maughan, Eduardo Díaz-Rubio, Benoist Chibaudel, Kaitlyn K.H. Goey
Publikováno v:
Journal of Clinical Oncology. 35:e15044-e15044
e15044 Background: iCTx in pts with aCRC offers potential for improvement in QoL. The COIN trial is the largest study to compare iCTx v. continuous strategies in aCRC, a pre-specified subgroup analysis of 16 baseline factors was undertaken among pts
Autor:
Wendy W.J. de Leng, Miangela M. Lacle, Cornelis J. A. Punt, Stefan M. Willems, Eric Strengman, Ankie M.T. van der Velden, Miriam Koopman, C. Vreuls, Sjoerd G. Elias, Geert-Jan Creemers, Harm van Tinteren, Kaitlyn K.H. Goey
Publikováno v:
Journal of Clinical Oncology. 34:3525-3525
3525Background: The impact of KRAS mutation status in mCRC treated with anti-VEGF therapy is controversial. The randomized phase 3 CAIRO3 study showed benefit of first-line CAP-B maintenance treatm...
Autor:
Cornelis J. A. Punt, Alfredo Falcone, Daniel J. Sargent, Enrique Aranda, Kaitlyn K.H. Goey, Eduardo Díaz-Rubio, Qian Shi, Aimery de Gramont, Miriam Koopman, Volker Heinemann, Erin M. Green
Publikováno v:
Journal of Clinical Oncology. 34:658-658
658 Background: In patients (pts) with mCRC with an asymptomatic primary tumor, there is limited evidence regarding the indication for primary tumor resection. The primary objective was to evaluate the prognostic value of primary tumor resection in s